REFERENCES
- The ICD-10. Classification of mental and behavioral disorders. Geneva: World Health Organization: 1992. p. 86.
- Erlandsen C. Utproving av et nytt nevroleptikum, Leponex (clozapin) hos schizofrene med lang sykehistorie. Nord J Psy-chiatry 1981;3:248–53.
- Bakken K, Bratli T, Erlandsen C, Lingjwrde 0, Nome S. Local monitoring center for clozapine therapy: quality assurance of drug treatment in a group of psychiatric patients. Tidsskr Nor Laegeforen 1998;7: 1076–8.
- Lovdahl H. Skating av pasienttilstand GAF. Oslo: Department for Clinical Psychiatric Research, Ulleval Hospital. Internett address: http//www//transmit.no/gaf/.
- Andreasen NC, Nopoulos P, Schultz S, Miller D, Gupata S, Swayze V, et al. Positive and negative symptoms of schizophre-nia. Acta Psychiatr Scand 1994;90 Suppl 384:51–9.
- Gerlach J. Extrapyramidal side effects. Nord J Psychiatry 1997;51 Suppl 40:25–9.
- Gerlach J. Clozapine side effects. Nord J Psychiatry 1997;51 Suppl 40:65–8.
- Rabinowitz T, Frankenburd FR, Kando J. The effect of cloza-pine on saliva flow rate: A pilot study. Biol Psychiatry 1996;40:1132–4.
- Norwegian Central Bureau of Statistics. Dodsarsaker, 1999, main tables. Oslo: Statistisk Sentralbyra.; 1995.
- Verghese C, DeLeon J, Nair C, Simpson GM. Clozapine with-drawal effects and receptor profiles of typical and atypical neu-roleptics. Biol Psychiatry 1996;39:135–8.
- Fleischacker WW, Meise U, Gunther V, Kurz M. Compliance with antipsychotic drug treatment: Influence of side effects. Acta Psychiatr Scand 1994;89 Suppl 382:11–5.
- Meltzer HY, Okayli G. Reduction of suicidality during clozap-Me treatment of neuroleptic-rasistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152:183–90.
- Nordby K, Wold S. Underveis. Stange, Norway: Hedmark County, Sanderud Hospital in co-operation with the High School in Hedmark, Department of Nursing.
- Andrew M. Legemidler og kvalitetssikring i sykehus-et ansvar ogsá for legene. Tidsskr Nor Laegeforen 1992;112:1877–80.
- Nylenna M. Gode journaler er god medisin. Tidsskr Nor Laegeforen 1992;112:3560–4.
- Ruud J. Men hjemme best. Langtidspsykiatriske pasienter i en kommunal omsorgs- og behandlingsmodell 1996. Oslo: Lwgeforeningens kvalitetssikringsfond; 1996.
- Fitton A, Benfield P. Clozapine. An appraisal of its pharma-coeconomic benefits in the treatment of schizophrenia. Phar-maeconomics 1993;4:131–56.
- Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993;162:38–42.
- Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, et al. Cost effectiveness of clozapine in neurolep-tic-resistant schizophrenia. Am J Psychiatry 1993;150:163–6.
- Reid WH, Mason M, Toprac M. Savings in hospital bed-days related to treatment with Clozapine. Hosp Community Psychi-atry 1994;45:261–4.
- Lindstrom LH. The effect of long-term treatment with clozap-Me in schizophrenia for up to 13 years. Acta Psychiatr Scand 1988;524–9.
- Grund J, Husbyn H. Okonomisk evaluering av legemidler. Oslo: Universitetsforlaget; 1993. p. 239–50.
- Lundberg T. Clozapine—an atypical nevroleptic. A pharma cokinetic, PET and clinical study. Uppsala Sweden: Uppsala University; 1995.
- Lingjwrde 0, Bela M, Kruger MB, Dahle LG, Fossheim I, Helle J, et al. Improvement patterns in schizophrenic Mon-re-sponders' treated with clozapine. A systematic study over 1 year. Nord J Psychiatry 1996;50: 457–67.